Record Details

A randomized controlled clinical trial and preclinical efficacy of an Ayurvedic formulation Arjuna Ksheerapaka Churna for dyslipidemia

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title A randomized controlled clinical trial and preclinical efficacy of an Ayurvedic formulation Arjuna Ksheerapaka Churna for dyslipidemia
 
Creator Timilsina, Khemraj
Mishra, Anjana
Patial, Vikram
Gupta, Mahesh
Chaudharya, Vijay
Singh, Damanpreet
 
Subject Ayurveda
Cardiovascular
Dyslipidemia
High-fat diet
Rosuvastatin
Terminalia arjuna
 
Description 519-529
Arjuna Ksheerapaka is an Ayurvedic formulation prepared as a milk decoction of the powdered bark of Terminalia
arjuna (Roxb.) Wight & Arn. It is clinically used for a variety of cardiovascular conditions. The current study investigated
the efficacy of Arjuna Ksheerapaka Churna (AKC) against dyslipidemia using a preclinical model and a randomized,
active-controlled clinical trial. Different groups of Sprague Dawley rats were fed with a high-fat diet (HFD) for 7 weeks,
followed by 4 weeks of AKC treatment. After that, biochemical and histopathological parameters were studied with
rosuvastatin as a reference standard. In the clinical study, 30 patients were randomized in 2 groups (n = 15/group) and
provided with AKC 6 g/day or rosuvastatin 10 mg/day orally for 8 weeks. The body mass index, serum biochemical, and
haematological parameters were studied at the baseline (start of the treatment) and endpoint (end of the treatment). In the
preclinical experiment, a marked decrease in the serum total cholesterol, low-density lipoprotein (LDL), triglycerides,
fasting blood glucose, and elevated high-density lipoprotein (HDL) was recorded in the AKC-treated groups compared to
the vehicle control. AKC administration also decreased the serum aminotransferases level in contrast to the rosuvastatin
treatment. The clinical study showed a marked reduction in triglycerides, total cholesterol, and LDL at the end of AKC
treatment compared to the baseline. The effectiveness of AKC on triglycerides, total cholesterol, and LDL reduction at the
endpoint was found to be equipotent to that of rosuvastatin. However, insignificant change was observed in the
haematological and other biochemical parameters in both groups at the endpoint compared with the baseline. The preclinical
results concluded AKC to be safer in a HFD rat model compared to rosuvastatin as it reduced the elevated serum
aminotransferases level. The clinical effectiveness of AKC was found to be equipotent to rosuvastatin. Both, clinical and
preclinical studies supported the therapeutic efficacy of AKC in dyslipidemia.
 
Date 2024-06-26T09:20:52Z
2024-06-26T09:20:52Z
2024-06
 
Type Article
 
Identifier 0975-1068 (Online); 0972-5938 (Print)
http://nopr.niscpr.res.in/handle/123456789/64091
https://doi.org/10.56042/ijtk.v23i6.2781
 
Language en
 
Relation Int Cl.24: A61K 36/00, A61K 9/00
 
Publisher NIScPR-CSIR, India
 
Source IJTK Vol.23(6) [June 2024]